

Supplementary Table 3. Baseline characteristics of eyes with type 2 diabetes mellitus and diabetic retinopathy, stratified by GLP-1 receptor agonist exposure status, before and after propensity score matching.

Characteristic	Unmatched No GLP-1 N = 1,541,807	Unmatched GLP-1 N = 175,168	Matched No GLP-1 N = 175,168	Matched GLP-1 N = 175,168
	n (%) or Mean (SD)	n (%) or Mean (SD)	n (%) or Mean (SD)	n (%) or Mean (SD)
Demographics				
Age, years	66 (13)	61 (11)	61 (13)	61 (11)
Female	769,926 (50%)	93,850 (54%)	93,927 (54%)	93,850 (54%)
Male	756,353 (49%)	79,623 (45%)	79,614 (45%)	79,623 (45%)
Unknown	15,528 (1.0%)	1,695 (1.0%)	1,627 (0.9%)	1,695 (1.0%)
Race				
Asian	42,118 (2.7%)	4,393 (2.5%)	4,331 (2.5%)	4,393 (2.5%)
Black or African American	158,345 (10%)	18,507 (11%)	18,241 (10%)	18,507 (11%)
Other	164,040 (11%)	20,029 (11%)	19,624 (11%)	20,029 (11%)
Unknown	435,734 (28%)	49,540 (28%)	49,486 (28%)	49,540 (28%)
White	741,570 (48%)	82,699 (47%)	83,486 (48%)	82,699 (47%)
Ethnicity				
Hispanic or Latino	133,579 (8.7%)	18,219 (10%)	17,701 (10%)	18,219 (10%)
Not Hispanic or Latino	812,739 (53%)	90,033 (51%)	90,277 (52%)	90,033 (51%)
Unknown	595,489 (39%)	66,916 (38%)	67,190 (38%)	66,916 (38%)
Eye Laterality				
Left	771,233 (50%)	87,659 (50%)	87,679 (50%)	87,659 (50%)
Right	770,574 (50%)	87,509 (50%)	87,489 (50%)	87,509 (50%)
Follow-up				
Follow-up duration, days	1,098 (856)	1,556 (837)	1,173 (878)	1,556 (837)
Socioeconomic Status (ZIP code level)				
Median household income < \$35,000	64,408 (4.2%)	7,107 (4.1%)	6,633 (3.8%)	7,107 (4.1%)
Median household income \$35,000–\$74,999	832,673 (54%)	97,209 (55%)	98,054 (56%)	97,209 (55%)
Median household income \$75,000–\$149,999	442,560 (29%)	46,937 (27%)	47,062 (27%)	46,937 (27%)
Median household income > \$150,000	18,114 (1.2%)	1,859 (1.1%)	1,778 (1.0%)	1,859 (1.1%)
Unknown	184,052 (12%)	22,056 (13%)	21,641 (12%)	22,056 (13%)
HS graduation rate ≤60%	18,528 (1.2%)	2,324 (1.3%)	2,479 (1.4%)	2,324 (1.3%)
HS graduation rate 61–70%	44,389 (2.9%)	6,019 (3.4%)	5,630 (3.2%)	6,019 (3.4%)
HS graduation rate 71–80%	145,384 (9.4%)	18,030 (10%)	17,514 (10%)	18,030 (10%)
HS graduation rate 81–90%	498,189 (32%)	55,928 (32%)	58,514 (33%)	55,928 (32%)
HS graduation rate 91–100%	655,119 (42%)	71,240 (41%)	69,841 (40%)	71,240 (41%)
Unknown	180,198 (12%)	21,627 (12%)	21,190 (12%)	21,627 (12%)
Urban/Rural				
Urban	1,335,680 (87%)	151,033 (86%)	151,023 (86%)	151,033 (86%)
Rural	200,642 (13%)	23,637 (13%)	23,704 (14%)	23,637 (13%)
Insurance Status				
Commercial	307,139 (20%)	54,081 (31%)	55,014 (31%)	54,081 (31%)
Medicaid	160,753 (10%)	30,307 (17%)	29,947 (17%)	30,307 (17%)
Medicare	1,029,263 (67%)	86,888 (50%)	86,426 (49%)	86,888 (50%)
Unknown	44,652 (2.9%)	3,892 (2.2%)	3,781 (2.2%)	3,892 (2.2%)
Smoking Status				
Current	112,049 (7.3%)	12,882 (7.4%)	12,735 (7.3%)	12,882 (7.4%)
Former	218,541 (14%)	21,236 (12%)	20,713 (12%)	21,236 (12%)
Never	860,187 (56%)	100,410 (57%)	101,453 (58%)	100,410 (57%)
Unknown	351,030 (23%)	40,640 (23%)	40,267 (23%)	40,640 (23%)
DR Severity at Index				
Mild NPDR	920,048 (60%)	100,925 (58%)	102,132 (58%)	100,925 (58%)
Moderate NPDR	286,725 (19%)	36,879 (21%)	34,984 (20%)	36,879 (21%)
Severe NPDR	84,082 (5.5%)	11,348 (6.5%)	10,532 (6.0%)	11,348 (6.5%)

PDR	250,952 (16%)	26,016 (15%)	27,520 (16%)	26,016 (15%)
Obesity Severity				
BMI < 30	895,976 (58%)	78,839 (45%)	97,983 (56%)	78,839 (45%)
BMI 30–39.9	448,225 (29%)	61,127 (35%)	52,778 (30%)	61,127 (35%)
BMI ≥ 40	197,606 (13%)	35,202 (20%)	24,407 (14%)	35,202 (20%)
Diabetes Medications at Index				
Biguanide (metformin)	341,824 (22%)	85,412 (49%)	85,671 (49%)	85,412 (49%)
DPP-4 inhibitor	111,646 (7.2%)	27,945 (16%)	27,910 (16%)	27,945 (16%)
Insulin	275,273 (18%)	69,457 (40%)	69,700 (40%)	69,457 (40%)
SGLT-2 inhibitor	136,314 (8.8%)	62,416 (36%)	60,330 (34%)	62,416 (36%)
Sulfonylurea	175,878 (11%)	43,024 (25%)	43,132 (25%)	43,024 (25%)
Thiazolidinedione (TZD)	40,335 (2.6%)	14,226 (8.1%)	13,547 (7.7%)	14,226 (8.1%)
Baseline Clinical Factors				
Visual acuity, logMAR	0.32 (0.51)	0.26 (0.43)	0.26 (0.41)	0.26 (0.43)
Diabetic macular edema	107,460 (7.0%)	12,893 (7.4%)	13,086 (7.5%)	12,893 (7.4%)
Epiretinal membrane	147,411 (9.6%)	11,554 (6.6%)	11,525 (6.6%)	11,554 (6.6%)
Ischemic maculopathy	8,155 (0.5%)	977 (0.6%)	1,005 (0.6%)	977 (0.6%)
Neovascular glaucoma	3,133 (0.2%)	260 (0.1%)	248 (0.1%)	260 (0.1%)
Retinal artery occlusion	7,217 (0.5%)	545 (0.3%)	547 (0.3%)	545 (0.3%)
Retinal vein occlusion	25,949 (1.7%)	2,044 (1.2%)	2,029 (1.2%)	2,044 (1.2%)
Retinal detachment	15,500 (1.0%)	1,522 (0.9%)	1,667 (1.0%)	1,522 (0.9%)
Vitreous hemorrhage	48,616 (3.2%)	5,173 (3.0%)	5,529 (3.2%)	5,173 (3.0%)
Wet AMD	24,176 (1.6%)	1,183 (0.7%)	1,023 (0.6%)	1,183 (0.7%)
Systemic Comorbidities				
Coronary artery disease	594,050 (39%)	56,156 (32%)	56,221 (32%)	56,156 (32%)
Chronic kidney disease	549,863 (36%)	45,847 (26%)	45,686 (26%)	45,847 (26%)
Hyperlipidemia	1,267,019 (82%)	144,290 (82%)	145,410 (83%)	144,290 (82%)
Hypertension	1,323,731 (86%)	149,201 (85%)	150,204 (86%)	149,201 (85%)

GLP-1 = Glucagon-like peptide-1, PDR = proliferative diabetic retinopathy, NPDR = non-proliferative diabetic retinopathy, DPP-4 = Dipeptidyl Peptidase IV, AMD = age-related macular degeneration.